The TAMs then inhibit tumor-infiltrating T cells directly through receptor-ligand cognates [e.g., PD-1:PD-L1 (84)] or by releasing anti-inflammatory cytokines (IL-10, TGF-β1, and IL-6). This evidence concerns the gene TGFB1 and neoplasm.